Miao-Yan Zhang

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 9

Top Topics

End Stage Renal Disease

Prognostic Factors

Ejection Fraction

Top Venues

British journal of haematology

Annals of hematology

International journal of hematology

Leukemia & lymphoma

This page only lists publications with an associated author ORCID identifier.

Publications

Yan-Ting Liu, Yu-Han Gao, Hao Zhao, Miao-Yan Zhang, Ming-Hui Duan, Jian Li, Lu Zhang
Sirolimus is effective for refractory/relapsed idiopathic multicentric Castleman disease: A single-center, retrospective study. Annals of hematology (2024)
Lu Zhang, Yu-Han Gao, Si-Yuan Li, Hao Zhao, Miao-Yan Zhang, Yan-Ying Yu, Yan-Ting Liu, Jian Li
A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman disease. International journal of hematology (2024)
Yu-Han Gao, Yan-Ting Liu, Miao-Yan Zhang, Si-Yuan Li, David C Fajgenbaum, Lu Zhang, Jian Li
Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival. British journal of haematology 204 (5) (2024)
Yu-Han Gao, Yan-Ting Liu, Miao-Yan Zhang, Si-Yuan Li, David C Fajgenbaum, Lu Zhang, Jian Li
Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival. British journal of haematology 204 (5) (2024)
Lu Zhang, Yu-Han Gao, Si-Yuan Li, Hao Zhao, Miao-Yan Zhang, Yan-Ying Yu, Yan-Ting Liu, Jian Li
A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman disease. International journal of hematology 119 (6) (2024)
Yu-Han Gao, Yan-Ting Liu, Miao-Yan Zhang, Si-Yuan Li, David C Fajgenbaum, Lu Zhang, Jian Li
Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival. British journal of haematology (2024)
Yu-Han Gao, Yan-Ting Liu, Miao-Yan Zhang, Si-Yuan Li, David C Fajgenbaum, Lu Zhang, Jian Li
Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival. British journal of haematology (2024)
Miao-Yan Zhang, Jian Li, Yi-Ning Wang, Zhuang Tian, Lu Zhang
Unicentric Castleman's disease presenting as amyloid A cardiac amyloidosis: a case report. Annals of hematology (2023)
Lu Zhang, Miao-Yan Zhang, Xin-Xin Cao, Dao-Bin Zhou, David C Fajgenbaum, Yu-Jun Dong, Jian Li
A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD. Leukemia & lymphoma 63 (3) (2022)